FDA Approves First Oral High-Risk Neuroblastoma Maintenance Therapy
The U.S. Food and Drug Administration (FDA) has recently approved the first and only oral maintenance therapy, Iwilfin (eflornithine), to strengthen the fight against aggressive childhood cancer, specifically high-risk neuroblastoma. This approval marks a significant advancement in the treatment of this condition, providing a new and much-needed treatment option for both adult and paediatric patients. […]
FDA Approves First Oral High-Risk Neuroblastoma Maintenance Therapy Read More »










